BiondVax Pharmaceuticals Ltd. (TASE:BNDX) has been invited to give a presentation about the results of the clinical trials of its universal flu vaccine at the upcoming World Health Organization's (WHO) first conference on such vaccines in Hong Kong in January 2013. The WHO is responsible for global monitoring of influenza and issues guidelines to governments about vaccine preparations and global readiness to deal with seasonal influenza outbreaks and possible pandemics.
BiondVax said that it considers the invitation as international recognition of the progress in its clinical trials to develop a universal flu vaccine.
In a second announcement, BiondVax said that the Office of the Chief Scientist has approved the company's NIS 6.5 million R&D plan, of which the government will finance 40%. The Chief Scientist also approved NIS 2 million, of which it will finance 30%, for the preclinical and clinical development of the company’s M-001 multimeric flu vaccine.
Earlier this year, BiondVax successfully completed a Phase II clinical trial of its M-001 flu vaccine on the elderly. The trial's results strengthen the results of three previous human clinical trials, which found that the vaccine was safe and effective across all ages (18-91). The company has obtained Good Manufacturing Practices (GMP) from the EU regulator, allowing the company to conduct clinical trials in Europe.
Published by Globes [online], Israel business news - www.globes-online.com - on November 14, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012